20
Participants
Start Date
March 11, 2024
Primary Completion Date
March 11, 2025
Study Completion Date
March 11, 2025
TIRZEPATIDE
Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
Florida Academic Centers Research and Education, LLC
INDUSTRY